GlassScriptPhysician profile
Sarah R Cheyette
NPI 1003983032
$14,251.45
in general payments reported to CMS, 2019-2025
13 companies · $6,647 in 2025
The $6,647 reported for 2025 was more than what 88% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $331 · 2021: $563 · 2022: $5,574 · 2023: $602 · 2024: $128 · 2025: $6,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,348 · Travel and Lodging: $993 · Food and Beverage: $536 · Honoraria: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,347.50 |
| Travel and Lodging | $993.48 |
| Food and Beverage | $536.16 |
| Honoraria | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $6,513.63 | 2025 | Jornay Pm |
| Tris Pharma INC | $6,246.86 | 2020-2025 | Dyanavel Xr, Quillichew Er, Quillivant |
| Sunovion Pharmaceuticals INC. | $495.43 | 2019-2021 | |
| Corium, LLC | $224.54 | 2021-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $218.73 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $139.08 | 2020-2022 | |
| Neos Therapeutics, LP | $126.27 | 2019 | |
| Jazz Pharmaceuticals INC. | $98.82 | 2022 | |
| Ucb, INC. | $65.82 | 2020-2022 | |
| Shire North American Group INC | $45.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $28.13 | 2019 | |
| Abbvie INC. | $24.20 | 2021 | |
| Ironshore Pharmaceuticals INC. | $24.12 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Cheyette listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.